CN103748229A - 改进的杆状病毒表达系统 - Google Patents

改进的杆状病毒表达系统 Download PDF

Info

Publication number
CN103748229A
CN103748229A CN201280037489.9A CN201280037489A CN103748229A CN 103748229 A CN103748229 A CN 103748229A CN 201280037489 A CN201280037489 A CN 201280037489A CN 103748229 A CN103748229 A CN 103748229A
Authority
CN
China
Prior art keywords
recombinant
baculovirus
gene
genome
baculoviruses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280037489.9A
Other languages
English (en)
Chinese (zh)
Inventor
莱昂内尔·加利贝尔
奥托-维海姆·莫腾
莫尼克·凡奥尔斯
克里斯特尔·里维埃
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genethon
Original Assignee
Genethon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genethon filed Critical Genethon
Publication of CN103748229A publication Critical patent/CN103748229A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14051—Methods of production or purification of viral material
    • C12N2710/14052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201280037489.9A 2011-07-27 2012-07-27 改进的杆状病毒表达系统 Pending CN103748229A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161512142P 2011-07-27 2011-07-27
US61/512,142 2011-07-27
PCT/EP2012/064843 WO2013014294A2 (en) 2011-07-27 2012-07-27 Improved baculovirus expression systems

Publications (1)

Publication Number Publication Date
CN103748229A true CN103748229A (zh) 2014-04-23

Family

ID=46640007

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280037489.9A Pending CN103748229A (zh) 2011-07-27 2012-07-27 改进的杆状病毒表达系统

Country Status (10)

Country Link
US (1) US10480010B2 (enExample)
EP (1) EP2737071B1 (enExample)
JP (1) JP6122430B2 (enExample)
CN (1) CN103748229A (enExample)
BR (1) BR112014001863A2 (enExample)
CA (1) CA2842392C (enExample)
DK (1) DK2737071T3 (enExample)
ES (1) ES2623780T3 (enExample)
IN (1) IN2014CN00688A (enExample)
WO (1) WO2013014294A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114317608A (zh) * 2020-12-28 2022-04-12 陕西杆粒生物科技有限公司 一种基因敲除型杆状病毒表达载体

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
RU2716991C2 (ru) 2014-11-05 2020-03-17 Вояджер Терапьютикс, Инк. Полинуклеотиды aadc для лечения болезни паркинсона
RU2716422C2 (ru) 2014-11-14 2020-03-11 Вояджер Терапьютикс, Инк. Композиции и способы лечения бокового амиотрофического склероза (als)
CN112410339A (zh) 2014-11-14 2021-02-26 沃雅戈治疗公司 调节性多核苷酸
HK1245326A1 (zh) * 2014-12-12 2018-08-24 Voyager Therapeutics, Inc. 用於生产scaav的组合物和方法
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189959A1 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
CN109831916B (zh) 2016-05-18 2023-07-21 沃雅戈治疗公司 治疗亨廷顿氏舞蹈病的组合物和方法
CA3252099A1 (en) 2016-05-18 2025-06-05 Voyager Therapeutics, Inc. MODULATING POLYNUCLEOTIDES
EP3506817A4 (en) 2016-08-30 2020-07-22 The Regents of The University of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
JP2020518259A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ハンチントン病治療組成物および方法
JP2020518258A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 筋萎縮性側索硬化症（ａｌｓ）治療組成物および方法
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
WO2019018342A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. NETWORK EQUIPMENT TRACK GUIDE SYSTEM
KR102850887B1 (ko) 2017-08-03 2025-08-28 보이저 테라퓨틱스, 인크. Aav의 전달을 위한 조성물 및 방법
MX2020003042A (es) 2017-09-29 2020-11-18 Voyager Therapeutics Inc Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
US20200237799A1 (en) 2017-10-16 2020-07-30 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
CN119242711A (zh) 2017-10-16 2025-01-03 沃雅戈治疗公司 肌萎缩性侧索硬化症（als）的治疗
BR112020023082A2 (pt) 2018-05-15 2021-02-09 Voyager Therapeutics, Inc. composições e métodos para o tratamento de doença de parkinson
CA3114621A1 (en) 2018-09-28 2020-04-02 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
CA3115248A1 (en) * 2018-10-05 2020-04-09 Voyager Therapeutics, Inc. Engineered nucleic acid constructs encoding aav production proteins
CA3116701A1 (en) * 2018-10-15 2020-04-23 Voyager Therapeutics, Inc. Expression vectors for large-scale production of raav in the baculovirus/sf9 system
CN109609552B (zh) * 2018-12-28 2020-04-14 中国科学院武汉物理与数学研究所 重组腺相关病毒的制备方法、系统及重组杆粒
EP3924364A1 (en) 2019-02-15 2021-12-22 Sangamo Therapeutics, Inc. Compositions and methods for producing recombinant aav
KR102272651B1 (ko) * 2019-03-28 2021-07-02 충북대학교 산학협력단 외래단백질의 발현량과 발현시간이 증대된 배큘로바이러스
CA3144437A1 (en) * 2019-06-26 2020-12-30 Virovek, Inc. Baculovirus expression system
EP4229204A1 (en) 2020-10-15 2023-08-23 F. Hoffmann-La Roche AG Nucleic acid constructs for simultaneous gene activation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1205741A (zh) * 1995-12-22 1999-01-20 纳幕尔杜邦公司 重组杆状病毒的生产

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE78293T1 (de) 1983-05-27 1992-08-15 Texas A & M Univ Sys Verfahren zur herstellung eines rekombinanten baculovirus-expressionsvektors.
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
DK518384A (da) 1984-01-31 1985-07-01 Idaho Res Found Vektor til fremstilling af et gen-produkt i insektceller, fremgangsmaade til dens fremstilling samt dens anvendelse
FR2664905B1 (fr) * 1990-07-18 1994-08-12 Agronomique Inst Nat Rech Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1205741A (zh) * 1995-12-22 1999-01-20 纳幕尔杜邦公司 重组杆状病毒的生产

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GAILBERT L ET AL: "Baculovirus deleted for chitinase, cathepsin and p10 genes improves purified rAAV8 quality", 《INTERNET CITATION》, 1 January 2010 (2010-01-01), pages 1 *
RICHARD B HITCHMAN ET AL: "Genetic modification of a baculovirus vector for increased expression in insect cells", 《CELL BIOLOGY AND TOXICOLOGY》, vol. 26, no. 1, 5 August 2009 (2009-08-05), pages 57 - 68, XP019767524 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114317608A (zh) * 2020-12-28 2022-04-12 陕西杆粒生物科技有限公司 一种基因敲除型杆状病毒表达载体
CN114317608B (zh) * 2020-12-28 2023-08-22 陕西杆粒生物科技有限公司 一种基因敲除型杆状病毒表达载体

Also Published As

Publication number Publication date
JP6122430B2 (ja) 2017-04-26
CA2842392C (en) 2020-09-15
ES2623780T3 (es) 2017-07-12
DK2737071T3 (en) 2017-05-08
BR112014001863A2 (pt) 2017-02-21
US20140356904A1 (en) 2014-12-04
EP2737071B1 (en) 2017-03-15
CA2842392A1 (en) 2013-01-31
JP2014522658A (ja) 2014-09-08
IN2014CN00688A (enExample) 2015-04-03
EP2737071A2 (en) 2014-06-04
US10480010B2 (en) 2019-11-19
WO2013014294A3 (en) 2013-04-04
WO2013014294A2 (en) 2013-01-31

Similar Documents

Publication Publication Date Title
DK2737071T3 (en) IMPROVED BACULOVIRUS EXPRESSION SYSTEMS
RU2739596C2 (ru) Продуцирование aav в клетках насекомых, способы и композиции для этого
US10767192B2 (en) Baculovirus system for the expression of a gene therapy vector
CN109311932A (zh) 提高杆状病毒系统产生的重组腺相关病毒的生物学效力的方法
JP7134240B2 (ja) 組換え型アデノ随伴ウイルスの調製方法、システム及び組換え型バクミド
Wu et al. Development of versatile and flexible Sf9 packaging cell line-dependent OneBac system for large-scale recombinant adeno-associated virus production
US12473571B2 (en) Expression cassette for expressing gene comprising overlapping open reading frames in insect cell and application thereof
WO2020072844A1 (en) Engineered nucleic acid constructs encoding aav production proteins
JP2025029161A (ja) バキュロウイルス発現系
Wu et al. The influence of serial passage on the stability of an exogenous gene expression in recombinant baculovirus
US12416019B2 (en) Expression cassette containing overlapping open reading frames and application
WO2025165781A1 (en) Stable recombinant virus and methods of use thereof
Aurelien et al. Advantages of homologous recombination-over transposition-based systems to generate recombinant baculovirus for AAV vector production
TW202311528A (zh) 大規模腺相關病毒產生系統
CN117925723A (zh) 一种杆状病毒-rAAV生产系统中转移载体pAAV-Donor的制备方法及应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20140423

RJ01 Rejection of invention patent application after publication